XFOR - NASDAQ

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc.

XFOR·NASDAQ

$4.01

-0.74%
HealthcareBiotechnology

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$378.22M
EPS-1.8700
P/E Ratio-2.14
Earnings Date08/06/2026
X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. Fair Value Envelope

XFOR · NASDAQ

Our analysis suggests that XFOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.01, this represents a potential HIDDEN relative to our calculated worth for X4 Pharmaceuticals, Inc..

HIDDEN
Intrinsic Value
Current Price: $4.01

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$3.8B
+ Cash & Equivalents$217.0M
Firm Value-$3.5B
- Debt$77.3M
Equity Value-$3.6B
/ Shares Outstanding11,408,300B
DCF Value-$317
OVERVALUED BY 8009%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$116.3M
-$158.1M
-$214.8M
-$292.0M
-$396.7M
-$539.1M
-$732.6M
-$995.5M
-$1.4B
-$1.8B
Maintenance CapEx
-$815.3K
-$1.1M
-$1.5M
-$2.0M
-$2.8M
-$3.8M
-$5.1M
-$7.0M
-$9.5M
-$12.9M
Owner Earnings
-$117.2M
-$159.2M
-$216.3M
-$294.0M
-$399.5M
-$542.9M
-$737.7M
-$1.0B
-$1.4B
-$1.9B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$108.5M
-$136.5M
-$171.7M
-$216.1M
-$271.9M
-$342.1M
-$430.5M
-$541.6M
-$681.5M
-$857.5M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your XFOR research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.